Overall, these findings highlight the potential role of liquid biopsy in combination with specific pathways influenced by KRAS and TP53 mutations, as well as the significance of TP53 in suppressing malignant transformation and shaping genomic signatures in pancreatic cancer. This evidence concerns the gene TP53 and pancreatic neoplasm.